Landos’ unique core platform technology enables accelerated development of safer, more effective oral, first-in-class therapeutics for autoimmune diseases. Landos has identified Lanthionine Synthetase C-Like 2 (LANCL2) as a novel therapeutic target for autoimmune diseases, including inflammatory bowel disease (IBD); Crohn’s disease (CD) and ulcerative colitis (UC). Based on extensive preclinical studies, Landos has validated a unique mechanism of action involving LANCL2 that exerts potent anti-inflammatory effects with an outstanding safety profile.
landosbiopharma.com
Location: United States, Virginia, Blacksburg
Total raised: $86.7M
Investors 2
| Date | Name | Website |
| - | Perceptive... | perceptive... |
| - | Xontogeny | xontogeny.... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 05.01.2023 | - | $16.7M | - |
| 13.08.2019 | Series B | $60M | Perceptive... |
| 22.09.2017 | Series A | $10M | Perceptive... |
Mentions in press and media 19
| Date | Title | Description | Source |
| 25.03.2024 | AbbVie Gets Another Ulcerative Colitis Contender via $137M L... | AbbVie already has blockbuster drugs for ulcerative colitis, but that isn’t stopping the pharmaceuti... | medcitynew... |
| 05.01.2023 | Landos Biopharma Provides Comprehensive Update on Clinical D... | Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase ... | einpresswi... |
| 05.01.2023 | Landos Biopharma Announces $16.7 Million Private Placement F... | - | globenewsw... |
| 05.01.2023 | Landos Biopharma Announces $16.7 Million Private Placement F... | NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. LABP ("Landos" or the &... | einpresswi... |
| 24.06.2022 | After seven months of searching, Landos hires a CEO; Mar... | Gregory Oakes Landos Biopharma has landed a new CEO after seven months of being led by an i... | endpts.com... |
| 15.11.2021 | Landos Biopharma : Reports Third Quarter 2021 Financial Resu... | Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update Enhancin... | marketscre... |
| 15.11.2021 | Landos Biopharma Reports Third Quarter 2021 Financial Result... | Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization R... | marketscre... |
| 20.08.2019 | Landos Biopharma Announces First Patient Dosed in Global Pha... | – Global clinical trial underway in 11 countries, including U.S., European, and Eastern European sit... | venturebea... |
| 15.08.2019 | Blacksburg Pharmaceutical Startup Raises $60M for Autoimmune... | In what could prove to be 2019's largest funding round in Central Virginia, a Blacksburg pharmaceuti... | bizjournal... |
| 13.08.2019 | Landos Biopharma Completes $60 Million Series B Financing | BLACKSBURG, Va.--(BUSINESS WIRE)--Landos Biopharma, Inc., a clinical-stage biopharmaceutical company... | citybizlis... |
Show more